title: Components of the metabolic syndrome in long-term survivors of testicular cancer.
abstract: BACKGROUND
  A possible explanation of the excess cardiovascular risk in testicular cancer (TC) survivors is development of metabolic syndrome. The association between metabolic syndrome and TC treatment is examined in long-term survivors.
  
  
  METHODS
  In a national follow-up study (1998-2002), 1463 TC survivors (diagnosed 1980-1994) participated. Patients >60 years were excluded in the present study, leaving 1135 patients eligible. The patients were divided in four treatment groups: surgery (n = 225); radiotherapy (n = 446) and two chemotherapy groups: cumulative cisplatin dose (Cis) <or=850 mg (n = 376) and Cis >850 mg (n = 88). A control group consisted of 1150 men from the Tromsø Population Study. Metabolic syndrome was defined according to a modified National Cholesterol Education Program definition.
  
  
  RESULTS
  Both chemotherapy groups had increased odds for metabolic syndrome compared with the surgery group, highest for the Cis >850 group [odds ratio (OR) 2.8, 95% confidence interval (CI) 1.6-4.7]. Also, the Cis >850 group had increased odds (OR 2.1, 95% CI 1.3-3.4) for metabolic syndrome compared with the control group. The association between metabolic syndrome and the Cis >850 group was strengthened after adjusting for testosterone, smoking, physical activity, education and family status.
  
  
  CONCLUSIONS
  TC survivors treated with cisplatin-based chemotherapy have an increased risk of developing metabolic syndrome compared with patients treated with other modalities or with controls.
authors.affiliation: Department of Oncology, Institute of Clinical Medicine, University of Tromsø, Norway. hegesa@fagmed.uit.no
authors.forename: H S
authors.initials: HS
authors.lastname: Haugnes
authors.forename: N
authors.initials: N
authors.lastname: Aass
authors.forename: S D
authors.initials: SD
authors.lastname: Fosså
authors.forename: O
authors.initials: O
authors.lastname: Dahl
authors.forename: O
authors.initials: O
authors.lastname: Klepp
authors.forename: E A
authors.initials: EA
authors.lastname: Wist
authors.forename: J
authors.initials: J
authors.lastname: Svartberg
authors.forename: T
authors.initials: T
authors.lastname: Wilsgaard
authors.forename: R M
authors.initials: RM
authors.lastname: Bremnes
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000209:etiology*; D008875:Middle Aged; D012307:Risk Factors; D017741:Survivors; D013736:Testicular Neoplasms / Q000150:complications / Q000401:mortality* / Q000628:therapy; D013997:Time Factors